CORT Corcept Therapeutics
- 23.500
- +0.700+3.07%
Corcept Therapeutics News
HC Wainwright & Co. : Corcept Therapeutics (CORT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $38.00.
Corcept Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $38 Price Target
Analysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Zevra Therapeutics (ZVRA) and Corcept Therapeutics (CORT)
Truist Financial Gives a Buy Rating to Corcept Therapeutics (CORT)
Corcept Therapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Bio-Rad Laboratories (BIO)
Analysts' Top Healthcare Picks: AngioDynamics (ANGO), Corcept Therapeutics (CORT)
Corcept Therapeutics: Hold Rating Amidst Generic Competition and Legal Challenges
Leerink Partners Keeps Their Hold Rating on Corcept Therapeutics (CORT)
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Incyte (INCY) and Nkarta (NKTX)
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), Intellia Therapeutics (NTLA) and Corcept Therapeutics (CORT)
Leerink Partners Keeps Their Hold Rating on Corcept Therapeutics (CORT)
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $28
Corcept Therapeutics Analyst Ratings
Balancing Near-term Risks With Long-term Potential: A Buy Rating for Corcept Therapeutics
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $38
Corcept Therapeutics Analyst Ratings
Corcept Therapeutics (CORT) Gets a Buy From Piper Sandler
Analysis
Price Target
No Data
